Spire Wealth Management Acquires New Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Spire Wealth Management bought a new position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 36,900 shares of the company’s stock, valued at approximately $53,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Synovus Financial Corp bought a new stake in shares of Tenaya Therapeutics in the 3rd quarter worth approximately $28,000. SG Americas Securities LLC purchased a new position in Tenaya Therapeutics in the 3rd quarter worth $49,000. Atticus Wealth Management LLC lifted its stake in Tenaya Therapeutics by 56.3% in the fourth quarter. Atticus Wealth Management LLC now owns 47,762 shares of the company’s stock worth $68,000 after purchasing an additional 17,199 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Tenaya Therapeutics by 43.2% during the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock valued at $72,000 after buying an additional 7,000 shares during the period. Finally, XTX Topco Ltd grew its stake in shares of Tenaya Therapeutics by 51.2% during the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock valued at $95,000 after buying an additional 16,687 shares during the last quarter. 90.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a report on Monday, February 3rd. Canaccord Genuity Group reissued a “buy” rating and set a $16.00 price objective on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Piper Sandler restated an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Leerink Partners reiterated an “outperform” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Finally, Chardan Capital reissued a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research report on Wednesday, December 18th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tenaya Therapeutics currently has an average rating of “Buy” and a consensus target price of $17.33.

Tenaya Therapeutics Stock Performance

Shares of TNYA stock opened at $0.96 on Monday. Tenaya Therapeutics, Inc. has a fifty-two week low of $0.95 and a fifty-two week high of $7.01. The firm has a market cap of $76.41 million, a P/E ratio of -0.67 and a beta of 2.84. The business’s 50 day moving average price is $1.78 and its 200-day moving average price is $2.19.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.